サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1550796

エクソソームの世界市場 - 市場規模、予測、試験、動向 (2024年)

The Global Exosome Market - Market Size, Forecast, Trials and Trends, 2024

出版日
発行
BioInformant
ページ情報
英文 351 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
エクソソームの世界市場 - 市場規模、予測、試験、動向 (2024年)
出版日: 2024年09月09日
発行: BioInformant
ページ情報: 英文 351 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エグゼクティブサマリー

エクソソームはエンドソームに由来する細胞外小胞 (EV) で、その大きさは30～150ナノメートルです。ほぼすべての種類の細胞から分泌されるエクソソームは、細胞特異的なタンパク質、脂質、核酸を運び、受容細胞に選択的に吸収されることで、細胞間のコミュニケーションにおいて重要な役割を果たしています。

エクソソーム技術における最近の進歩は、リキッドバイオプシー、精密医療、再生医療におけるエクソソームの利用拡大を促しています。特にがん由来のエクソソームは、血管新生・転移・免疫を制御する能力で価値があり、がんの検出・診断・治療選択に極めて重要です。

エクソソームカーゴは、がんだけでなく、心血管疾患・腎疾患・神経変性疾患・代謝性疾患など、さまざまな疾患の予後に関する知見を提供します。エクソソーム内に数多くの生体分子が存在することが発見されたことで、検出・モニタリング・治療のためのがんバイオマーカーとしての利用に関する広範な研究が拍車をかけています。

エクソソームは血清・血漿・尿・唾液など多くの生体液中に存在するため、低侵襲診断に理想的です。また、予後の指標や治療効果の予測因子としても機能します。さらに、エクソソームは治療への応用も研究されています。例えば、エクソソームは、欠陥分子や欠損分子に起因する疾患の標的治療のために、治療用siRNAやタンパク質を運ぶように設計することができます。間葉系幹細胞 (MSC) 由来のエクソソームは、炎症を抑え、瘢痕組織の形成を防ぎ、免疫反応を調節する可能性を示しています。

かつては過小評価されていたエクソソーム分野は、現在急速に発展しています。最近の論文では、米国の著者と中国の研究者の業績が際立っており、特にKarolinska InstitutetのSusanne Gabrielsson博士とUnicyte AGが関連する科学文献をリードしています。

BioInformant社の世界戦略レポートは、特許、助成金、出版物、臨床試験の動向など、急成長するエクソソーム市場を詳述しています。業界内の提携、企業合併・買収 (M&A)、資金調達についても考察し、競合情勢や2030年までの市場予測も掲載しています。

エクソソームを用いた診断薬や治療薬は拡大しており、現在388件の臨床試験が進行中です。エクソソーム治療薬はまだ販売承認を受けていませんが、2029年までに最初の5つの製品が登場すると予想されています。エクソソームは、標的への送達、副作用の軽減、免疫検出の回避など、従来の治療法に比べて有望な利点を提供します。

エクソソームは医療用途に加え、皮膚の若返り、創傷治癒、傷跡の修正、毛髪の再生を促進するために化粧品にも使用されています。エクソソームベースの診断薬2種は、すでに米国FDAからファスト・トラック認可を受けています。

この包括的なレポートは以下の情報を提供します：

  • 市場分析：エクソソーム治療薬・診断薬、製品/サービス、製造技術、化粧品用途
  • エクソソーム治療薬の臨床試験パイプライン (未感作・人造エクソソームの両方を含む)
  • エクソソーム診断法を活用した承認済みおよび今後の製品
  • 臨床試験活動：種類別・地域別・相別・出資者別
  • 主要な業界指標の分析：科学論文、特許、助成金、臨床試験など
  • 主な資金調達イベント (M&A、資金調達イベント、共同開発契約、IPOを含む)
  • 戦略的パートナーシップと競合考察
  • 市場規模 (市場セグメント別、地域別) とその予測 (2030年まで)
  • 業界動向と今後の方向性

当レポートは、エクソソーム治療薬・診断薬や研究製品、製造技術、化粧品、RTU (Ready-to-Use) エクソソームを開発している企業に市場情報を提供することを目的としています。エクソソーム市場は競合企業が多いため、当レポートは、調査に膨大な時間を費やすことなく、常に情報を入手し、チャンスをつかむための貴重なリソースを提供します。

目次

第1章 調査概要

第2章 エクソソームの生物学と機能：概要

  • エクソソームの構造
    • エクソソームの分子含有量
    • エクソソームの膜と内腔の構成要素
    • エクソソームの由来による分類
    • 合成エクソソーム
  • 細胞治療と遺伝子治療の違い
  • 細胞療法からエクソソーム療法への移行
  • 今後10年間のエクソソーム

第3章 エクソソームエンジニアリング：新しい技術プラットフォーム

  • 内部修飾
    • 分離前の内部修飾方法
    • インキュベーション
    • 遺伝子編集
    • 分離後の内部修飾方法
  • 表面改質
    • 親細胞による表面改質
    • 直接表面改質
    • エクソソーム内の分子の表示
  • 内部修飾
    • 分離前の内部修飾方法
    • 分離後の修飾方法
  • 表面・内部改質エクソソーム
    • エクソソーム腔内に充填された親水性カーゴの事例

第4章 エクソソームに関する科学刊行物

  • エクソソーム診断法・治療法の出版動向
  • 主要技術による治療用エクソソームに関するPubMed刊行物
  • PubMedのエクソソーム分離と精製に関する技術論文
  • 薬物キャリアとしての脂質ナノ粒子とエクソソームに関するPubMed論文
  • エクソソーム刊行物の分布：疾患の種類別
  • エクソソーム刊行物：がんの種類別

第5章 エクソソーム特許の概要

  • エクソソームの特許公開の推移
  • エクソソーム特許：治療用と診断用
  • エキソソーム特許出願：エキソソームの供給源別
  • 特許/特許出願：分離・精製技術別
  • 特許/特許出願：カーゴの種類別
  • 特許/特許出願：カーゴの積載方法別
  • 特許/特許出願：治療分野別
  • エクソソーム特許の主要譲受人
    • 特許取得済みの分離・調製技術の種類：譲受人別
    • 譲受人が使用するカーゴの種類
    • カーゴの積載方法：譲受人別
    • 治療領域：譲受人別
    • 譲受人のカテゴリー
  • エキソソーム特許の出願件数：管轄地域別
  • エクソソーム特許の出願人
  • エクソソーム特許の発明者
  • エキソソーム特許の所有者
  • エクソソーム特許の法的地位

第6章 エクソソーム：臨床試験の情勢

  • エクソソーム臨床試験：研究段階別
  • エクソソーム臨床試験：資金提供者タイプ別
  • エクソソーム臨床試験：技術別
  • エクソソームを用いた疾患治療の臨床試験の現状
  • 診断研究のためのエクソソームを用いた臨床試験
  • 主要なエクソソーム研究開発企業
  • 前臨床開発中のエクソソーム治療薬

第7章 エクソソーム分離/精製技術：概要

  • 超遠心分離 (UC)
    • 分画超遠心分離
    • 密度勾配超遠心分離 (DGU)
  • 限外濾過 (UF)
    • タンデム構成の限外濾過
    • 連続限外濾過
  • サイズ排除クロマトグラフィー (SEC)
  • ポリマー沈殿法
  • 免疫親和性捕捉法
  • アプタマーベースの方法
  • マイクロ流体技術

第8章 エクソソーム企業の独自技術プラットフォーム

  • 選択されたエクソソーム技術プラットフォームの解説
    • AGLE-102
    • Hybridosome
    • AB126　
    • CAP-1002 (Deramiocel)
    • REGENT
    • ExoFlo
    • DeliverEX
    • EXOVEX
    • ExoSCRT
    • LEAP
    • ExoDx
    • EXPLOR
    • Exo-Target

第9章 エクソソームエンジニアリング技術：概要

  • 孵化法
  • トランスフェクション法
  • 超音波処理法
  • エレクトロポレーション法
  • 押出法
  • 凍結融解法
  • 遺伝子エンジニアリング的手法

第10章 エクソソームの治療への応用：概要

  • エクソソーム治療分野の主要企業
    • Nano24のEXO-CD24 (OBCTCD24)
    • The Hemopurifier
    • Carmine TherapeuticsのREGENT
    • Ciolaのエクソソームカスタマイズ技術
    • Capricor TherapeuticsのCAP-1002 (Deramioce)
    • ILIAS BiologicsのEXPLOR
    • Aruna BioのAB126　
    • Aegle TherapeuticsのAGLE-102
    • OmniSpirant TherapeuticsのOmniSomes
    • Exogenus TherapeuticsのEXO-101
    • RIONの精製エクソソーム製品 (PEP)

第11章 エクソソームの診断への応用

  • 診断用途における利点
  • 診断に重点を置く主な適応症
  • 最も一般的な標的エクソソームバイオマーカー
    • 診断用途のエクソソームタンパク質
    • がん診断薬としてのエクソソームmiRNA
  • 診断用エクソソームの研究
  • エクソソーム診断薬の開発における主要企業
    • BioFluidicaのLiquidScan
    • ExoCanのExoEnrich
    • Exosome Diagnostics, Inc.のExoDx前立腺検査
    • エクソソームサイエンスのタウソーム検査
    • Exosomics SpAによるがん診断
    • Guardant HealthのGuardant360 CDx
    • Mursla Bioによる肝臓がん検出研究
    • NanoSomiXのBDEバイオマーカーアッセイ
    • Theoria ScienceのExoScreenアッセイ

第12章 美容におけるエクソソームの応用

  • 美容エクソソーム治療
    • 顔の若返りにおけるエクソソーム
    • 育毛におけるエクソソーム
    • 傷跡軽減におけるエクソソーム
    • 豊胸手術におけるエクソソーム
  • 美容目的のエクソソームの供給源
  • 皮膚科学に関連するエクソソームの科学
  • 主要プレーヤーと製品
  • 人気のエクソソームベースの美容
    • AnteAGE Proシステム
    • CartessaのExoCR
    • ELEVAI LabsのELEVAI enfinity
    • ExoceuticalsのEXO PLUS
    • Kimera LabsのVive
    • RION AestheticsのCALM Serum
    • ExoCoBioのASCE Exosomes

第13章 エキソソーム分野における取引と資金調達

  • エクソソーム企業へのベンチャーキャピタル資金
    • EXO Biologics
    • Exogenus Therapeutics
    • INEXOPLAT
    • Mantra Bio
    • Anjarium Biosciences
    • Evox Therapeutics, Ltd.
    • ILIAS Biologics
    • ExoCoBio, Inc.
    • Aegle Therapeutics
    • Evox Therapeutics
    • Evox Therapeutics
    • Codiak BioSciences
    • Codiak BioSciences
    • Exosome Diagnostics
    • Exosome Diagnostics, Inc
    • EXOバイオロジクス
  • エキソソーム分野におけるパートナーシップ契約
    • CytivaとRooster Bio
    • SomesTechとConvEyXO
    • RoosterBio, Inc.とFUJIFILM Diosynth Biotechnologies
    • Evox TherapeuticsとEli Lilly
    • ExopharmとAstellas
    • Univercells TechnologiesとRoosterBio
    • AgeX TherapeuticsとUCI
    • VivaZomeとLa Trobe University
    • Evotec SEとCurexsys GmbH
    • Bio-TechneとQIAGEN
    • InnoCan PharmaとRecipharms
    • Codiak BioSciencesとSarepta
    • Evox TherapeuticsとTakeda
    • PureTechとRoche
    • Evox TherapeuticsとBoehringer Ingelheim
    • Sarpeta TherapeuticsとCodiak Biosciences
    • Navigo ProteinsとMDimune
    • Jazz PharmaceuticalsとCodiak BioSciences
    • Exosome DiagnosticsとIntezyne
    • Evox TherapeuticsとBoehringer Ingelheim
  • 企業買収取引
    • ExoCoBioとBENEV
    • Evox TherapeuticsとCodiak Biosciences' Technology
    • LonzaとExosomics
    • LonzaとCodiak Biosciences
    • Bio-Techne CorporationとExosome Diagnostics
    • LonzaとHansaBioMed
  • ライセンス取引
    • EVerZomとErganeo
    • Elevai LabsとYuva Biosciences
    • TOPPANとDai Nippon Toryo
    • Carnegie Mellon University (CMU)とCoya Therapeutics
    • INOVIQ, Ltd.とResearchDx, Inc.
    • ATUMとCodiak BioSciences
    • Johns Hopkins UniversityとCapricor Therapeutics
    • Evox TherapeuticsとEli Lily
    • Codiak BioSciencesとSarepta
    • VivaZome TherapeuticsとUniversity of Adelaide
    • Evox TherapeuticsとTakeda
    • CEVECとEvox Therapeutics
    • OrgenesisとExcella Bio
    • System BiosciencesとQIAGEN
    • PureTech Healthと3D Biotechnologies
  • 新規株式公開
    • Elevai Labs
    • Codiak Biosciences
    • Codiak Biosciences
    • Codiak BioSciences

第14章 エクソソーム市場分析

  • エクソソーム治療薬の市場
  • 世界のRTU (Ready-to-Use) 精製エクソソーム市場：種類別
    • エクソソームの市場規模：親細胞の種類別
  • エクソソーム診断薬の市場
  • 世界のエクソソーム技術市場：製品種類別
  • 世界のエクソソームベース美容品 (化粧品) 市場
  • エクソソームの市場全体
  • エクソソーム療法の市場牽引役

第15章 エクソソーム市場の競合企業のプロファイル

  • 101 Bio
  • Abbexa, Ltd.
  • AcouSort AB
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • Akrivis Health Care Pvt., Ltd.
  • AM BioTech
  • AMS Biotechnology, Ltd. (AMSBIO)
  • AnteAGE
  • Aposcience AG
  • Aruna Bio
  • BENEV Company, Inc. (ExoCoBio)
  • BioCat GmbH
  • BioFluidica
  • Biological Dynamics, Inc.
  • Biorbyt, Ltd.
  • Bioscience Institute
  • Biosynth International, Inc.
  • BreStem Therapeutics, Inc.
  • Capricor Therapeutics
  • Carmine Therapeutics
  • Cellarcus Biosciences, Inc.
  • Cell Care Therapeutics
  • Cells for Cells
  • Cell Guidance Systems, Ltd.
  • Ciloa
  • ConvEyXO
  • Craif, Inc.
  • Creative Bioarray
  • Creative Biostructure
  • Creative Biolabs
  • Creative Medical Technology Holdings, Inc.
  • Creative Proteomics
  • CUSABIO Technology LLC
  • Diadem Biotherapeutics
  • Direct Biologics
  • Elevai Labs, Inc.
  • Entelexo Biotherapeutics
  • EriVan Bio
  • EVerZom
  • Evolutionary Biologics, Inc.
  • Evomic Science LLC
  • Evox Therapeutics, Ltd.
  • EXO Biologics
  • ExoCan Healthcare Technologies Pvt., Ltd.
  • Exocel Bio
  • Exogenus Therapeutics
  • Exokeryx, Inc.
  • ExoProTher Medical
  • ExoQure
  • EXORPHIA, Inc.
  • ExosomeDx (biotechne)
  • ExosomePlus
  • Exosome Sciences
  • ExoStemTech Co., Ltd.
  • ExoVectory
  • ExSURE Pvt. Ltd.
  • Florica Therapeutics
  • HansaBioMed Life Sciences, Ltd.
  • ILIAS Biologics, Inc.
  • INEXOPLAT, Inc.
  • Innocan Pharma
  • Innovex Therapeutics, SL
  • INOVIQ, Ltd.
  • Irazu Oncology
  • Izon Science, Ltd.
  • Kimera Labs, Inc.
  • Leading Biology, Inc.
  • LifeSpan Biosciences, Inc.
  • Lonza Group, Ltd.
  • Mantra Bio
  • Mercury Bio
  • Mercy Bioanalytics
  • Micregen, Ltd.
  • Microgentas
  • miR Scientific
  • Liver EV Liquid Biopsy Platform
  • MyBioSource, Inc.
  • Nano 24 (OBCDCT24)
  • NanoSomiX, Inc.
  • Nanovex Biotechnologies
  • NeurExo Sciences
  • NeuroDex, Inc.
  • Norgen Biotek Corporation
  • Novaxomx GmbH
  • Novus Biologicals
  • NurExone Biologic, Inc.
  • Oasis Diagnostics Corporation
  • NX Prenatal, Inc.
  • OmniSpirant Therapeutics
  • OncoXome, Inc.
  • Paracrine Therapeutics Pte, Ltd.
  • QIAGEN
  • Reactive Medical Labs
  • ReNeuron
  • RION Aesthetics, Inc.
  • Rivela Diagnostics
  • RoosterBio, Inc.
  • ShiftBIO
  • SOL Bio Corporation
  • SomesTech
  • Stem Cell Medicine, Ltd.
  • System Biosciences
  • Theoria Science, Inc.
  • TheraXyte
  • Thermo Fisher Scientific
  • TheraXyte Bioscience
  • The Tiny Cargo Company
  • TransGen Biotech, Co., Ltd.
  • Tymora Analytical
  • Unicyte AG
  • Urvogelbio Pvt, Ltd.
  • Versatope Therapeutics
  • VesiCURE Therapeutics
  • Vesigen Therapeutics, Inc.
  • VivaZome Therapeutics
  • ZEO ScientifiX, Inc.
  • Xosomix

図の索引

表の索引

目次

EXECUTIVE SUMMARY

Exosomes are extracellular vesicles (EVs) originating from endosomes, with sizes ranging from 30 to 150 nanometers. Secreted by nearly all cell types, exosomes play a key role in cell communication by carrying cell-specific proteins, lipids, and nucleic acids that are selectively absorbed by recipient cells.

Recent advancements in exosome technology are driving growth in their application across liquid biopsy, precision medicine, and regenerative medicine. Cancer-derived exosomes, in particular, are valuable for their ability to regulate angiogenesis, metastasis, and immunity, making them crucial for cancer detection, diagnosis, and treatment selection.

Exosome cargos offer prognostic insights for various diseases, including cardiovascular, renal, neurodegenerative, and metabolic disorders, as well as cancer. The discovery of numerous biomolecules within exosomes has spurred extensive research into their use as cancer biomarkers for detection, monitoring, and treatment.

Exosomes are present in many biofluids such as serum, plasma, urine, and saliva, making them ideal for minimally invasive diagnostics. They also serve as prognostic indicators and predictors of treatment responses. Furthermore, exosomes are being investigated for therapeutic use. For instance, exosomes can be engineered to carry therapeutic siRNA or proteins for targeted treatment of diseases caused by defective or missing molecules. Mesenchymal stem cell (MSC) derived exosomes have shown potential in reducing inflammation, preventing scar tissue formation, and modulating immune responses.

The exosome field, once underappreciated, is now rapidly evolving. Recent publications highlight the significant contributions of U.S. authors and Chinese researchers, with Dr. Susanne Gabrielsson from the Karolinska Institutet and Unicyte AG leading in relevant scientific literature.

BioInformant's global strategic report details the burgeoning exosome market, including trends in patents, grants, publications, and clinical trials. It covers industry partnerships, M&A activities, and financing, with insights into the competitive landscape and market forecasts through 2030.

Exosome-based diagnostics and therapeutics are expanding, with 388 clinical trials currently underway. Although no exosome therapeutics have received marketing approval yet, the first five products are anticipated by 2029. Exosomes offer promising advantages over traditional therapies, including targeted delivery, reduced side effects, and avoidance of immune detection.

In addition to medical applications, exosomes are also being used within cosmetics to promote skin rejuvenation, wound healing, scar revision, and hair restoration. Two exosome-based diagnostics have already received Fast Track approval from the U.S. FDA.

This comprehensive report provides:

  • Market analysis for exosome therapeutics, diagnostics, product/services, manufacturing technologies, and cosmetic applications
  • The clinical trial pipeline for exosome therapeutics, including both naive and engineered exosomes
  • Approved and forthcoming products leveraging exosome diagnostics
  • Clinical trial activity by type, region, phase, and sponsor
  • Analysis of key industry metrics, including scientific publications, patents, grants, and clinical trials
  • Key funding events, including M&A, financing events, co-development agreements, and IPOs
  • Strategic partnerships and competitive insights
  • Market size figures, broken down by market segment and geography, with forecasts through 2030
  • Industry trends and future directions

This report is designed to inform market competitors who are developing exosome therapeutics, diagnostics, research products, manufacturing technologies, cosmeceuticals, and of course, ready-to-use exosomes. With the competitive nature of the exosome market, this report offers a valuable resource to stay informed and seize opportunities, without spending countless hours on research.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Target Demographic
  • 1.3. Report Sources
  • 1.4. Purpose of the Report
  • 1.5. Executive Summary
  • 1.6. Introduction

2. BIOLOGY & FUNCTIONS OF EXOSOMES: AN OVERVIEW

  • 2.1. Structure of an Exosome
    • 2.1.1. Molecular Contents of Exosomes
      • 2.1.1.1. Proteins in Exosomes
      • 2.1.1.2. Lipid Contents of Exosomes
      • 2.1.1.3. Nucleic Acids in Exosomes
    • 2.1.2. Membrane and Lumen Components of Exosomes
    • 2.1.3. Classification of Exosomes by Origin
      • 2.1.3.1. Natural Exosomes
        • 2.1.3.1.1. Isolation of Natural Exosomes
      • 2.1.3.2. Modified Exosomes
        • 2.1.3.2.1. Types of Therapeutic Cargos Loaded into Exosomes
        • 2.1.3.2.2. Biomedical Applications of Engineered Exosomes
    • 2.1.4. Synthetic Exosomes
  • 2.2. Differences between Cell Therapy and Gene Therapy
  • 2.3. The Shift from Cell Therapy to Exosome Therapy
  • 2.4. Exosomes in the Next Ten Years

3. EXOSOME ENGINEERING: A NEW TECHNOLOGY PLATFORM

  • 3.1. Interior Modification
    • 3.1.1. Pre-Isolation Interior Modification Methods
    • 3.1.2. Incubation
    • 3.1.3. Gene Editing
    • 3.1.4. Post-Isolation Interior Modification Methods
  • 3.2. Surface Modifications
    • 3.2.1. Surface Modification through Parent Cell
    • 3.2.2. Direct Surface Modification
    • 3.2.3. Displayed Molecules in Exosomes
  • 3.3. Interior Modification
    • 3.3.1. Pre-Isolation Interior Modification
    • 3.3.2. Post-Isolation Modification Methods
  • 3.4. An Exosome Showing Modified Surface and Modified Interior
    • 3.4.1. Examples of Hydrophilic Cargo Loaded into Exosome Lumen

4. SCIENTIFIC PUBLICATIONS ON EXOSOMES

  • 4.1. Publication Trends of Exosome Diagnostics and Therapeutics
  • 4.2. PubMed Publications on Therapeutic Exosomes by Loading Technology
  • 4.3. PubMed Papers on Exosome Isolation & Purification by Technology
  • 4.4. PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
  • 4.5. Distribution of Exosome Publications by Disease Type
  • 4.6. Exosome Publications by Cancer Type

5. EXOSOME PATENTS: AN OVERVIEW

  • 5.1. Exosome Patent Publications over Time
  • 5.2. Exosome Patents: Therapeutic vs. Diagnostics
  • 5.3. Exosome Patent Applications by Exosome Source
  • 5.4. Patents/Patent Applications by Isolation/Purification Technologies
  • 5.5. Patents/Patent Applications by Type of Cargo
  • 5.6. Patents/Patent Applications by Cargo Loading Methods
  • 5.7. Patents/Patent Applications by Therapy Area
  • 5.8. Leading Assignees of Exosome Patents
    • 5.8.1. Types of Patented Isolation/Preparations Technologies by Assignees
    • 5.8.2. Types of Cargos Employed by Assignees
    • 5.8.3. Cargo Loading Methods by Assignees
    • 5.8.4. Therapy Areas by Assignees
    • 5.8.5. Assignee Categories
  • 5.9. Exosome Patent Applications by Jurisdiction
  • 5.10. Exosome Patent Applicants
  • 5.11. Exosome Patent Inventors
  • 5.12. Exosome Patent Owners
  • 5.13. Legal Status of Exosome Patents

6. EXOSOMES: CLINICAL TRIAL LANDSCAPE

  • 6.1. Exosome Clinical Trials by Phase of Study
  • 6.2. Exosome Clinical Trials by Funder Type
  • 6.3. Exosome Clinical Trials by Technology
  • 6.4. Current Status of Clinical Trials using Exosomes in Treating Diseases
  • 6.5. Clinical Trials using Exosomes for Diagnostic Studies
  • 6.6. Major Exosome R&D Companies
  • 6.7. Exosome Therapeutics in Preclinical Development

7. EXOSOME ISOLATION/PURIFICATION TECHNOLOGIES: BRIEF OVERVIEW

  • 7.1. Ultracentrifugation (UC)
    • 7.1.1. Differential Ultracentrifugation
    • 7.1.2. Density Gradient Ultracentrifugation (DGU)
  • 7.2. Ultrafiltration (UF)
    • 7.2.1. Tandem-Configured Ultrafiltration
    • 7.2.2. Sequential Ultrafiltration
  • 7.3. Size Exclusion Chromatography (SEC)
  • 7.4. Polymer Precipitation Method
  • 7.5. Immunoaffinity Capture Method
  • 7.6. Aptamer-Based Method
  • 7.7. Microfluidic Technique

8. PROPRIETARY TECHNOLOGY PLATFORMS OF EXOSOME COMPANIES

  • 8.1. Description of Select Exosome Technology Platforms
    • 8.1.1. AGLE-102
    • 8.1.2. Hybridosome
    • 8.1.3. AB126
    • 8.1.4. CAP-1002 (Deramiocel)
    • 8.1.5. REGENT
    • 8.1.6. ExoFlo
    • 8.1.7. DeliverEX
    • 8.1.8. EXOVEX
    • 8.1.9. ExoSCRT
    • 8.1.10. LEAP
    • 8.1.11. ExoDx
    • 8.1.12. EXPLOR
    • 8.1.13. Exo-Target

9. EXOSOME ENGINEERING TECHNOLOGIES: AN OVERVIEW

  • 9.1. Incubation Method
  • 9.2. Transfection Method
  • 9.3. Sonication Method
  • 9.4. Electroporation Method
  • 9.5. Extrusion Method
  • 9.6. Freeze/Thaw Method
  • 9.7. Genetic Engineering Method

10. THERAPEUTIC APPLICATIONS OF EXOSOMES: A BRIEF OVERVIEW

  • 10.1. Key Players in the Exosome Therapeutic Space
    • 10.1.1. EXO-CD24 from Nano24 (OBCTCD24)
    • 10.1.2. The Hemopurifier
      • 10.1.2.1. Hemopurifier in Cancer
      • 10.1.2.2. Hemopurifier in Infectious Diseases
    • 10.1.3. REGENT from Carmine Therapeutics
    • 10.1.4. Exosome Customization Technology from Ciola
    • 10.1.5. CAP-1002 (Deramioce) from Capricor Therapeutics
    • 10.1.6. EXPLOR from ILIAS Biologics
    • 10.1.7. AB126 from Aruna Bio
    • 10.1.8. AGLE-102 from Aegle Therapeutics
    • 10.1.9. OmniSomes from OmniSpirant Therapeutics
    • 10.1.10. EXO-101 from Exogenus Therapeutics
    • 10.1.11. Purified Exosome Product (PEP) from RION

11. DIAGNOSTIC APPLICATIONS OF EXOSOMES

  • 11.1. Advantages in Diagnostic Applications
  • 11.2. Major Indications Focused for Diagnosis
  • 11.3. Most Common Targeted Exosome Biomarkers
    • 11.3.1. Exosomal Proteins for Diagnostic Applications
    • 11.3.2. Exosomal miRNAs as Cancer Diagnostic Agents
  • 11.4. Diagnostic Exosome Research
  • 11.5. Key Players in the Development of Exosome Diagnostics
    • 11.5.1. LiquidScan from BioFluidica
    • 11.5.2. ExoEnrich from ExoCan
    • 11.5.3. ExoDx Prostate Test from Exosome Diagnostics, Inc.
    • 11.5.4. TauSome Test from Exosome Sciences
    • 11.5.5. Cancer Diagnosis from Exosomics S.p.A
    • 11.5.6. Guardant360 CDx from Guardant Health
    • 11.5.7. Liver Cancer Detection study by Mursla Bio
    • 11.5.8. BDE Biomarker Assay from NanoSomiX
    • 11.5.9. ExoScreen Assay from Theoria Science

12. APPLICATIONS OF EXOSOMES IN AESTHETICS

  • 12.1. Aesthetic Exosome Treatments
    • 12.1.1. Exosomes in Facial Rejuvenation
    • 12.1.2. Exosomes in Hair Restoration
    • 12.1.3. Exosomes in Scar Reduction
    • 12.1.4. Exosomes in Breast Augmentation
  • 12.2. Sources of Exosomes for Aesthetic Use
  • 12.3. Science behind Dermatologically Relevant Exosomes
  • 12.4. Key Players & Products
  • 12.5. Popular Exosome-Based Aesthetics
    • 12.5.1. AnteAGE Pro System
    • 12.5.2. ExoCR from Cartessa
    • 12.5.3. ELEVAI enfinity from ELEVAI Labs
    • 12.5.4. EXO PLUS from Exoceuticals
    • 12.5.5. Vive from Kimera Labs
    • 12.5.6. CALM Serum from RION Aesthetics
    • 12.5.7. ASCE Exosomes from ExoCoBio

13. DEALS AND FUNDRAISING IN EXOSOME SPACE

  • 13.1. Venture Capital Funding for Exosome companies
    • 13.1.1. EXO Biologics
    • 13.1.2. Exogenus Therapeutics
    • 13.1.3. INEXOPLAT
    • 13.1.4. Mantra Bio
    • 13.1.5. Anjarium Biosciences
    • 13.1.6. Evox Therapeutics, Ltd.
    • 13.1.7. ILIAS Biologics
    • 13.1.8. ExoCoBio, Inc.
    • 13.1.9. Aegle Therapeutics
    • 13.1.10. Evox Therapeutics
    • 13.1.11. Evox Therapeutics
    • 13.1.12. Codiak BioSciences
    • 13.1.13. Codiak BioSciences
    • 13.1.14. Exosome Diagnostics
    • 13.1.15. Exosome Diagnostics, Inc
  • 13.2. Partnership Deals in Exosome Space
    • 13.2.1. Cytiva & Rooster Bio
    • 13.2.2. SomesTech & ConvEyXO
    • 13.2.3. RoosterBio, Inc. & FUJIFILM Diosynth Biotechnologies
    • 13.2.4. Evox Therapeutics & Eli Lilly
    • 13.2.5. Exopharm & Astellas
    • 13.2.6. Univercells Technologies & RoosterBio
    • 13.2.7. AgeX Therapeutics & UCI
    • 13.2.8. VivaZome & La Trobe University
    • 13.2.9. Evotec SE & Curexsys GmbH
    • 13.2.10. Bio-Techne & QIAGEN
    • 13.2.11. InnoCan Pharma & Recipharms
    • 13.2.12. Codiak BioSciences & Sarepta
    • 13.2.13. Evox Therapeutics & Takeda
    • 13.2.14. PureTech & Roche
    • 13.2.15. Evox Therapeutics & Boehringer Ingelheim
    • 13.2.16. Sarpeta Therapeutics & Codiak Biosciences
    • 13.2.17. Navigo Proteins & MDimune
    • 13.2.18. Jazz Pharmaceuticals & Codiak BioSciences
    • 13.2.19. Exosome Diagnostics & Intezyne
    • 13.2.20. Evox Therapeutics & Boehringer Ingelheim
  • 13.3. Acquisition Deals
    • 13.3.1. ExoCoBio & BENEV
    • 13.3.2. Evox Therapeutics & Codiak Biosciences' Technology
    • 13.3.3. Lonza & Exosomics
    • 13.3.4. Lonza & Codiak Biosciences
    • 13.3.5. Bio-Techne Corporation & Exosome Diagnostics
    • 13.3.6. Lonza & HansaBioMed
  • 13.4. Licensing Deals
    • 13.4.1. EVerZom & Erganeo
    • 13.4.2. Elevai Labs & Yuva Biosciences
    • 13.4.3. TOPPAN & Dai Nippon Toryo
    • 13.4.4. Carnegie Mellon University (CMU) & Coya Therapeutics
    • 13.4.5. INOVIQ, Ltd. & ResearchDx, Inc.
    • 13.4.6. ATUM & Codiak BioSciences
    • 13.4.7. Johns Hopkins University & Capricor Therapeutics
    • 13.4.8. Evox Therapeutics & Eli Lily
    • 13.4.9. Codiak BioSciences & Sarepta
    • 13.4.10. VivaZome Therapeutics & University of Adelaide
    • 13.4.11. Evox Therapeutics & Takeda
    • 13.4.12. CEVEC & Evox Therapeutics
    • 13.4.13. Orgenesis & Excella Bio
    • 13.4.14. System Biosciences & QIAGEN
    • 13.4.15. PureTech Health & 3D Biotechnologies
  • 13.5. IPO
    • 13.5.1. Elevai Labs
    • 13.5.2. Codiak Biosciences
    • 13.5.3. Codiak Biosciences
    • 13.5.4. Codiak BioSciences

14. EXOSOME MARKET ANALYSIS

  • 14.1. Market for Exosome Therapeutics
  • 14.2. The Global Market for Ready-to-Use Purified Exosomes by Type
    • 14.2.1. Market Size of Exosomes by Parent Cell Type
  • 14.3. Market for Exosome Diagnostics
  • 14.4. Global Exosome Technologies Market by Product Type
  • 14.5. Global Exosome-Based Aesthetics (Cosmeceuticals) Market
  • 14.6. The Overall Market for Exosomes
  • 14.7. The Market Driver of Exosome Therapies

15. PROFILES OF EXOSOME MARKET COMPETITORS

  • 15.1. 101 Bio
    • 15.1.1. PureExo Exosome Isolation Kit
  • 15.2. Abbexa, Ltd.
  • 15.3. AcouSort AB
    • 15.3.1. Technology: Acoustic Separation
    • 15.3.2. EIC Award
  • 15.4. Aegle Therapeutics
    • 15.4.1. Research & Development
  • 15.5. Aethlon Medical, Inc.
    • 15.5.1. Hemopurifier
  • 15.6. Akrivis Health Care Pvt., Ltd.
  • 15.7. AM BioTech
    • 15.7.1. Bio-Pulsed Technology
    • 15.7.2. ExoGiov
    • 15.7.3. LA EXO Exosome Cosmetics
  • 15.8. AMS Biotechnology, Ltd. (AMSBIO)
  • 15.9. AnteAGE
    • 15.9.1. At-Home Skincare Products
    • 15.9.2. At-Home Brow & Lash Products
    • 15.9.3. VRS Box (6 Pack) [$150]
    • 15.9.4. Professional Skincare Products
    • 15.9.5. Growth Factor Microneedling Products
    • 15.9.6. Stem Cell Facial Microchanneling Products
    • 15.9.7. Medical Skin Care Products
    • 15.9.8. Growth Factor Skin Treatment Products
    • 15.9.9. Growth Factor Hair Regeneration Products
  • 15.10. Aposcience AG
    • 15.10.1. Wound Healing
    • 15.10.2. Myocardial Infarction
  • 15.11. Aruna Bio
    • 15.11.1. AB126 (Neural Exosome)
  • 15.12. BENEV Company, Inc. (ExoCoBio)
    • 15.12.1. Exosome Regenerative Complex
    • 15.12.2. Exosome Regenerative Complex +
    • 15.12.3. EXO-XOM Facial
  • 15.13. BioCat GmbH
    • 15.13.1. ExoQuick Exosome Precipitation
    • 15.13.2. Exosome RNA & DNA Purification
    • 15.13.3. Exosome RNA Amplification & Profiling
    • 15.13.4. Exosome Quantification
    • 15.13.5. Exosome Antibody Array
    • 15.13.6. ExoGlow EV Labeling Kits
    • 15.13.7. Exosome Engineering
  • 15.14. BioFluidica
    • 15.14.1. LiquidScan
    • 15.14.2. Exosome Isolation
  • 15.15. Biological Dynamics, Inc.
    • 15.15.1. Verita Technology
    • 15.15.2. ExoVerita Pro Exosome Enrichment Platform
    • 15.15.3. Exosome Isolation & Analysis Services
  • 15.16. Biorbyt, Ltd.
  • 15.17. Bioscience Institute
    • 15.17.1. Bioscience Clinic Middle East
    • 15.17.2. Bioscience Genomics
    • 15.17.3. Services
      • 15.17.3.1. ExoSkin Therapy
      • 15.17.3.2. ExoHair Therapy
      • 15.17.3.3. ExoJoints Therapy
      • 15.17.3.4. ExoMale Therapy
      • 15.17.3.5. ExoFemale Therapy
      • 15.17.3.6. XOLINE Exosome Cosmetics
  • 15.18. Biosynth International, Inc.
    • 15.18.1. ME Kit (Microvesicle Extraction Kit)
  • 15.19. BreStem Therapeutics, Inc.
  • 15.20. Capricor Therapeutics
    • 15.20.1. Portfolio
    • 15.20.2. StealthX Technology
  • 15.21. Carmine Therapeutics
    • 15.21.1. REGENT Platform
  • 15.22. Cellarcus Biosciences, Inc.
    • 15.22.1. vFC Vesicle Analysis Assays
    • 15.22.2. vTAG Antibodies
    • 15.22.3. Vesicles and Vesicle Assay Standards
  • 15.23. Cell Care Therapeutics
    • 15.23.1. CCT-101
  • 15.24. Cells for Cells
    • 15.24.1. Current Clinical Trial using Exosomes
  • 15.25. Cell Guidance Systems, Ltd.
    • 15.25.1. Exosome Products
    • 15.25.2. Exo-spin Purification
    • 15.25.3. ExoLISA Technology: Exosome Detection
    • 15.25.4. Exosome Validated Antibodies
    • 15.25.5. Instant Exosomes
    • 15.25.6. NTA Size Profiling Service
  • 15.26. Ciloa
    • 15.26.1. Antibodies against Undruggable Targets
    • 15.26.2. Adjuvant & Virus-Free Vaccines
    • 15.26.3. Virus-Free Therapeutic Vectors
    • 15.26.4. Technology
  • 15.27. ConvEyXO
    • 15.27.1. Exo-Harvest Technology
    • 15.27.2. XomeXBio Technology
  • 15.28. Craif, Inc.
    • 15.28.1. NANO IP (Nano Intelligence Platform)
  • 15.29. Creative Bioarray
    • 15.29.1. Exosome Antibodies
    • 15.29.2. Exosome DNA-RNA Extraction Kits
    • 15.29.3. Exosome Isolation Tools
    • 15.29.4. Exosome Standards
    • 15.29.5. Fluorescent Exosome Standards
    • 15.29.6. Liquid Biopsy
    • 15.29.7. Exosome Research Services
  • 15.30. Creative Biostructure
    • 15.30.1. Exosome Products
    • 15.30.2. Exosome Services
      • 15.30.2.1. Exosome Isolation Services
      • 15.30.2.2. Exosome Analysis Services
      • 15.30.2.3. Exosome Characterization Services
      • 15.30.2.4. Exosome Engineering Services
      • 15.30.2.5. Exosome In Vitro Functional Assay
      • 15.30.2.6. Exosome In Vitro Functional Assay
  • 15.31. Creative Biolabs
    • 15.31.1. Exosome Products
    • 15.31.2. Exosome Isolation Tools
    • 15.31.3. Exosome Capture & Quantification Kits
    • 15.31.4. Exosome Antibody Products
    • 15.31.5. Exosome Standards
    • 15.31.6. Exosome Labeling Kits
    • 15.31.7. Exosomes Surface Modification Kits
    • 15.31.8. Exosome Identification Kits
    • 15.31.9. Exosome Marker cDNA Plasmid Products
    • 15.31.10. Exosome Release Modulation Reagents
    • 15.31.11. LipidSync Exosomes
    • 15.31.12. Exosome Services
  • 15.32. Creative Medical Technology Holdings, Inc.
    • 15.32.1. AmnioStem Stroke Therapy
  • 15.33. Creative Proteomics
    • 15.33.1. Exosome Services
  • 15.34. CUSABIO Technology LLC
    • 15.34.1. Exosome Isolation Kits
  • 15.35. Diadem Biotherapeutics
    • 15.35.1. Technology
  • 15.36. Direct Biologics
    • 15.36.1. ExoFlo
    • 15.36.2. AmnioWrap
  • 15.37. Elevai Labs, Inc.
    • 15.37.1. ELEVAI enfinity
    • 15.37.2. ELEVAI empower
    • 15.37.3. ELEVAI Root Renewal System
  • 15.38. Entelexo Biotherapeutics
  • 15.39. EriVan Bio
    • 15.39.1. Services
    • 15.39.2. Research Products
  • 15.40. EVerZom
    • 15.40.1. EVerZom Platform
  • 15.41. Evolutionary Biologics, Inc.
    • 15.41.1. EXO ELIXIR
    • 15.41.2. EVO GROW
    • 15.41.3. EVO JEL
    • 15.41.4. EXO RNA
    • 15.41.5. EVO HYBRID
    • 15.41.6. EXO PERIO
  • 15.42. Evomic Science LLC
    • 15.42.1. ExoEZ Exosome Isolation Kit
  • 15.43. Evox Therapeutics, Ltd.
    • 15.43.1. Gene Therapy
    • 15.43.2. Gene Editing
    • 15.43.3. RNA Therapeutics
    • 15.43.4. Precision Therapeutic Targeting
    • 15.43.5. Protein Therapeutics
    • 15.43.6. Manufacturing Exosomes
    • 15.43.7. Focus on Rare Diseases
  • 15.44. EXO Biologics
    • 15.44.1. Lead Product Candidate
  • 15.45. ExoCan Healthcare Technologies Pvt., Ltd.
    • 15.45.1. ExoEnrich
    • 15.45.2. ExoEngineering
    • 15.45.3. SAC-3D
    • 15.45.4. Services
      • 15.45.4.1. Multiphenotype Screen
      • 15.45.4.2. Small Molecule Screening
      • 15.45.4.3. Exo-BiDD
  • 15.46. Exocel Bio
    • 15.46.1. Services
      • 15.46.1.1. Exosome Isolation via Ultracentrifugation
      • 15.46.1.2. Nanoparticle Analysis for Size Distribution and Concentration
      • 15.46.1.3. Custom Experiments with NTA
      • 15.46.1.4. Custom Growth Factors Production
    • 15.46.2. Products
      • 15.46.2.1. Exovex REVIVE
      • 15.46.2.2. Exovex RENEW
      • 15.46.2.3. Exovex REVEAL
      • 15.46.2.4. Exovex REFINE
      • 15.46.2.5. Exovex RESTORE
      • 15.46.2.6. Exovex EQUUSOME
      • 15.46.2.7. Exovex CANISOME
      • 15.46.2.8. Exovex FELISOM
  • 15.47. Exogenus Therapeutics
    • 15.47.1. Exo-101
    • 15.47.2. ExoWound
  • 15.48. Exokeryx, Inc.
    • 15.48.1. Demeter EVPrep
    • 15.48.2. ExoScan
  • 15.49. ExoProTher Medical
  • 15.50. ExoQure
    • 15.50.1. Technology
    • 15.50.2. Products
  • 15.51. EXORPHIA, Inc.
    • 15.51.1. Activation Technology to produce Prime-EV
    • 15.51.2. Modification Technology to Produce Smart-EV
    • 15.51.3. INPACT-EV Technology
    • 15.51.4. EV Analysis Technology: EV-QUEST
    • 15.51.5. EXORPHIA's Product Pipeline
  • 15.52. ExosomeDx (biotechne)
    • 15.52.1. ExoDx Prostate Test
    • 15.52.2. Pharma Services
    • 15.52.3. Biomarker Discovery Services
  • 15.53. ExosomePlus
    • 15.53.1. MSC-Derived Exosomes
    • 15.53.2. ExoCope Technology
  • 15.54. Exosome Sciences
    • 15.54.1. TauSome (Exosomal Tau) Biomarker
  • 15.55. ExoStemTech Co., Ltd.
    • 15.55.1. Cartisome
    • 15.55.2. EST-T-EXO
    • 15.55.3. Hepatosome
    • 15.55.4. Hypoxisome
    • 15.55.5. Exosome Manufacturing Platform
    • 15.55.6. Protein Loading & Delivery Platform
  • 15.56. ExoVectory
    • 15.56.1. Technology
    • 15.56.2. Therapeutic Areas Focused
    • 15.56.3. Exosome Immunotherapy for Cancer
    • 15.56.4. Exosome Gene Therapy
  • 15.57. ExSURE Pvt. Ltd.
  • 15.58. Florica Therapeutics
  • 15.59. HansaBioMed Life Sciences, Ltd.
    • 15.59.1. Products
    • 15.59.2. Services
  • 15.60. ILIAS Biologics, Inc.
    • 15.60.2. Cargo Loading Process
    • 15.60.3. Exo-Target: Platform Technology
  • 15.61. INEXOPLAT, Inc.
  • 15.62. Innocan Pharma
    • 15.62.1. Cannabidiol (CBD)-Loaded Exosomes
  • 15.63. Innovex Therapeutics, SL
    • 15.63.1. Research & Development
    • 15.63.2. Vaccine against Plasmodium vivax malaria (PvRexVac)
    • 15.63.3. Vaccine against COVID-19 (ExoCoVac)
    • 15.63.4. Vaccine against PRRSV (PrrsvExoVac)
  • 15.64. INOVIQ, Ltd.
    • 15.64.1. NETs Technology
    • 15.64.2. EXO-NET Pan Exosome
  • 15.65. Irazu Oncology
  • 15.66. Izon Science, Ltd.
    • 15.66.1. qEV Isolation
    • 15.66.2. qEV Automation
    • 15.66.3. qEV Zenco
    • 15.66.4. Robotic System for Diagnostic Development
    • 15.66.5. qEV Magnetic Concentration Kit
    • 15.66.6. Tunable Resistive Pulse Sensing (TRPS)
  • 15.67. Kimera Labs, Inc.
    • 15.67.1. Vive
    • 15.67.2. Luxir & Luxir+
  • 15.68. Leading Biology, Inc.
  • 15.69. LifeSpan Biosciences, Inc.
  • 15.70. Lonza Group, Ltd.
    • 15.70.1. Exosome Service
  • 15.71. Mantra Bio
    • 15.71.1. REVEAL
    • 15.71.2. Partnering
  • 15.72. Mercury Bio
    • 15.72.1. The Chimeric yEV System
  • 15.73. Mercy Bioanalytics
    • 15.73.1. The Mercy Halo Test
  • 15.74. Micregen, Ltd.
    • 15.74.1. Secretomix
  • 15.75. Microgentas
    • 15.75.1. Products
      • 15.75.1.1. Exo TFF
      • 15.75.1.2. ExoFilter
      • 15.75.1.3. ExoCAS-2 (Exosome Clustering and Scattering)
      • 15.75.1.4. ExoPAS Advanced (Exosome Precipitation and Scattering)
      • 15.75.1.5. miRQuick (Exosomal miRNA)
      • 15.75.1.6. PIBEX System
      • 15.75.1.7. Plant Exosomes for Cosmetics
      • 15.75.1.8. Centella Asiatica Extracellular Vesicles (CICA EVs)
    • 15.75.2. Services
  • 15.76. miR Scientific
    • 15.76.1. miR Sentinel
  • 15.77. Mursla Bio
    • 15.77.1. Liver EV Liquid Biopsy Platform
  • 15.78. MyBioSource, Inc.
  • 15.79. Nano 24 (OBCDCT24)
  • 15.80. NanoSomiX, Inc.
    • 15.80.1. Technology
  • 15.81. Nanovex Biotechnologies
    • 15.81.1. Technology
    • 15.81.2. Synthetic Exosomes
  • 15.82. NeurExo Sciences
    • 15.82.1. Research & Development Programs
  • 15.83. NeuroDex, Inc.
    • 15.83.1. ExoSORT
    • 15.83.2. Lumin-EV
    • 15.83.3. Alpha-synuclein Assay
    • 15.83.4. TDP43 Assay
    • 15.83.5. Synaptic Protein Assay
    • 15.83.6. Autophagy Assay
    • 15.83.7. Biomarker Discovery Services
    • 15.83.8. LuminEV Kit
  • 15.84. Norgen Biotek Corporation
    • 15.84.1. Exosome Kits
      • 15.84.1.1. Intact Exosome Purification
      • 15.84.1.2. RNA Isolation from Intact Exosomes
      • 15.84.1.3. Exosome Purification, Exosome RNA and Free-Circulating RNA Isolation
      • 15.84.1.4. RNA Isolation from Purified Intact Exosomes
      • 15.84.1.5. Exosome Depletion
      • 15.84.1.6. Exosome Labeling and Cleaning Kit
      • 15.84.1.7. Isolation Services
      • 15.84.1.8. Contract Manufacturing Services
  • 15.85. Novaxomx GmbH
    • 15.85.1. Technology
  • 15.86. Novus Biologicals
    • 15.86.1. Exosome Research Tools
  • 15.87. NurExone Biologic, Inc.
    • 15.87.1. ExoTherapy
  • 15.88. Oasis Diagnostics Corporation
    • 15.88.1. Pure.SAL
  • 15.89. NX Prenatal, Inc.
    • 15.89.1. Technology
  • 15.90. OmniSpirant Therapeutics
    • 15.90.1. OmniSome Therapeutic Platform
  • 15.91. OncoXome, Inc.
    • 15.91.1. OncoXome's Exosomes
  • 15.92. Paracrine Therapeutics Pte, Ltd.
    • 15.92.1. Science
  • 15.93. QIAGEN
    • 15.93.1. exoEasy Maxi Kit
    • 15.93.2. exoRNeasy Midi Kit
    • 15.93.3. mercury LNA miRNA Focus PCR Panels
    • 15.93.4. miRCURY Exosome Serum/Plasma Kit
  • 15.94. Reactive Medical Labs
  • 15.95. ReNeuron
    • 15.95.1. CustomEX - A Customizable Exosome Platform
  • 15.96. RION Aesthetics, Inc.
    • 15.96.1. Products
      • 15.96.1.1. INTENSE Serum
      • 15.96.1.2. DAILY Serum
      • 15.96.1.3. CALM Serum
      • 15.96.1.4. HAIR Serum
  • 15.97. Rivela Diagnostics
    • 15.97.1. Technology
  • 15.98. RoosterBio, Inc.
    • 15.98.1. MSC-derived Exosomes
    • 15.98.2. QuickShip Exosomes
    • 15.98.3. QuickShip MSC and Exosome Media
    • 15.98.4. XF Bioreactor MSC & EV Development Kits
    • 15.98.5. XF Bioreactor MSC & EV Scale-Up Kits
    • 15.98.6. XF Bioreactor MSC & EV Starter Kits
    • 15.98.7. RoosterCollect-EV-CC
  • 15.99. ShiftBIO
    • 15.99.1. NSM Platform Technology
  • 15.100. SOL Bio Corporation
    • 15.100.1. Business Model
    • 15.100.2. NeutraRelease Technology
    • 15.100.3. ExoMain
    • 15.100.4. ExoBead
  • 15.101. SomesTech
    • 15.101.1. Products & Solutions
      • 15.101.1.1. ExoNP
      • 15.101.1.2. ExoLoad
      • 15.101.1.3. AI + DDS
  • 15.102. Stem Cell Medicine, Ltd.
    • 15.102.1. SCM's Pipeline
  • 15.103. System Biosciences
    • 15.103.1. Products
      • 15.103.1.1. Exosome Isolation Products
      • 15.103.1.2. Exosome Detection Products
      • 15.103.1.3. Exosome Quantitation Products
      • 15.103.1.4. Exosome Labeling Kit Products
      • 15.103.1.5. Exosome Biomarker Discovery Products
      • 15.103.1.6. Exosome Engineering & Design Products
    • 15.103.2. Services
  • 15.104. Theoria Science, Inc.
    • 15.104.1. ExoScreen Technology
  • 15.105. TheraXyte
    • 15.105.1. TAXY - A Programmable Drug Delivery System
  • 15.106. Thermo Fisher Scientific
    • 15.106.1. Exosome Products for Testing & Research
  • 15.107. TheraXyte Bioscience
    • 15.107.1. TAXY
  • 15.108. The Tiny Cargo Company
  • 15.109. TransGen Biotech, Co., Ltd.
    • 15.109.1. Products
      • 15.109.1.1. TransExo Cell Media Exosome Kit
      • 15.109.1.2. TransExo Urine Exosome Kit
      • 15.109.1.3. TransExo Serum/Plasma Exosome Kit
      • 15.109.1.4. TransExo Serum/Plasma Exosome Total RNA Extraction Kit
      • 15.109.1.5. TransExo Serum/Plasma Exosome Total miRNA Extraction Kit
  • 15.110. Tymora Analytical
    • 15.110.1. Services
      • 15.110.1.1. Plasma Proteomics (PTMs)
      • 15.110.1.2. Urine Proteomics
      • 15.110.1.3. Saliva Proteomics
      • 15.110.1.4. Tissue Proteomics
  • 15.111. Unicyte AG
    • 15.111.1. Technology
  • 15.112. Urvogelbio Pvt, Ltd.
  • 15.113. Versatope Therapeutics
    • 15.113.1. Technology
    • 15.113.2. Universal Influenza Vaccine
  • 15.114. VesiCURE Therapeutics
    • 15.114.1. modEXO Platform
    • 15.114.2. dilEVery Delivery System
  • 15.115. Vesigen Therapeutics, Inc.
    • 15.115.1. ARMMs
    • 15.115.2. Disease Areas of Focus
      • 15.115.2.1. Ocular
      • 15.115.2.2. Immunology
      • 15.115.2.3. Neurology
      • 15.115.2.4. Hematology
  • 15.116. VivaZome Therapeutics
    • 15.116.1. VivaZome's Clinical Targets
  • 15.117. ZEO ScientifiX, Inc.
    • 15.117.1. Aesthetic Exosomes
    • 15.117.2. PPX
  • 15.118. Xosomix

INDEX OF FIGURE

  • FIGURE 2.1: Classification of Extracellular Vesicles
  • FIGURE 2.2: Exosome Formation
  • FIGURE 2.3: Exosome Uptake by Target Cells
  • FIGURE 2.4: Structure of an Exosome
  • FIGURE 2.5: Membrane Lumen Components of Exosomes
  • FIGURE 2.6: Classification of Exosomes by Origin
  • FIGURE 2.7: Exosome Isolation Methods
  • FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display
  • FIGURE 3.1: Pre-Isolation Interior Modification Methods
  • FIGURE 3.2: Post-Isolation Interior Modification Methods
  • FIGURE 3.3: Surface Modification through Parent Cell
  • FIGURE 3.4: Direct Surface Modification
  • FIGURE 3.5: Pre-Isolation Interior Modification Methods
  • FIGURE 3.6: Post-Isolation Interior Modification Methods
  • FIGURE 3.7: An Engineered Exosome showing Surface and Interior Modifications
  • FIGURE 4.1: Number of PubMed.gov Publications, 2000-2024
  • FIGURE 4.2: Publication Trends of Exosome Diagnostics and Therapeutics
  • FIGURE 4.3: Number of PubMed Papers on Exosome Cargo-Loading by Technology
  • FIGURE 4.4: PubMed Papers on Exosome Isolation & Purification by Technology
  • FIGURE 4.5: PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
  • FIGURE 4.6: Distribution of Exosome Publications by Disease Type
  • FIGURE 4.7: Exosome Publications by Cancer Type
  • FIGURE 5.1: Exosome Patent Publications over Time, 2000-June 2024
  • FIGURE 5.2: Exosome Patents: Therapeutic vs. Diagnostics
  • FIGURE 5.3: Exosome Patents/Patent Applications by Exosome Sources
  • FIGURE 5.4: Patents/Patent Applications by Isolation-Preparation Technologies
  • FIGURE 5.5: Patents/Patent Applications by Type of Cargo
  • FIGURE 5.6: Patents/Patent Applications by Cargo Loading Methods
  • FIGURE 5.7: Patents/Patent Applications by Therapy Area
  • FIGURE 5.8: Leading Assignees of Exosome Patents
  • FIGURE 5.9: Top Five Countries with Exosome Patents
  • FIGURE 6.1: Percent Share of Clinical Trials by Application
  • FIGURE 7.1: Schematic of Differential Ultracentrifugation
  • FIGURE 7.2: Schematic of Density Gradient Ultracentrifugation
  • FIGURE 7.3: Schematic of Tandem Configured Ultrafiltration
  • FIGURE 7.4: Sequential Ultrafiltration
  • FIGURE 7.5: Schematic of Size Exclusion Chromatography
  • FIGURE 7.6: Schematic of Polymer Precipitation Method
  • FIGURE 7.7: Schematic of Immunoaffinity Capture Method
  • FIGURE 7.8: Diagram of Working Principle of Microfluidic Device
  • FIGURE 9.1: Schematic of Incubation Method of Drug Loading
  • FIGURE 9.2: Schematic of Transfection Method
  • FIGURE 9.3: Schematic Illustration of Sonication Method
  • FIGURE 9.4: Schematic Illustration of the Principle of Electroporation
  • FIGURE 9.5: Schematic Illustration of Drug Loading by Extrusion Method
  • FIGURE 9.6: Schematic Illustration of Genetic Modification of Exosome
  • FIGURE 10.1: Schematic Illustration of the Structure of EXO-CD24
  • FIGURE 10.2: Aethlon's Hemopurifier
  • FIGURE 10.3: Ciola's Unique in vivo Technology
  • FIGURE 10.4: Schematic of EXPLOR
  • FIGURE 10.5: CNS Specificity of AB126
  • FIGURE 10.6: OmniSomes from OmniSpirant
  • FIGURE 10.7: EXO-101 from Exogenus
  • FIGURE 11.1: Great Things in Tiny Packages
  • FIGURE 11.2: Major Indications Focused for Diagnosis
  • FIGURE 11.3: LiquidScan from BioFluidica
  • FIGURE 11.4: Exosome Isolation by ExoEnrich
  • FIGURE 11.5: Features of ExoDx Prostate Test
  • FIGURE 11.6: ExoScreen Assay from Theoria Science
  • FIGURE 12.1: Exosomes in Facial Rejuvenation using DermaPen
  • FIGURE 12.2: Exosome Therapy for Hair Restoration
  • FIGURE 12.3: Exosomes in Scar Reuction
  • FIGURE 12.4: AnteAGE Pro System
  • FIGURE 12.5: ExoCR from Cartessa
  • FIGURE 12.6: ELEVAI enfinity
  • FIGURE 12.7: EXO PLUS from Exoceuticals
  • FIGURE 12.8: Vive from Kimera Labs
  • FIGURE 12.9: CALM Serum from RION Aesthetics
  • FIGURE 12.10: ASCE Exosomes from ExoCoBio
  • FIGURE 14.1: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
  • FIGURE 14.2: Global Market for Ready-to-Use Exosomes by Type, 2023
  • FIGURE 14.3: Global Exosome Therapy Market by Parent Cell Type, 2023
  • FIGURE 14.4: Global Market for Exosome Diagnostics by Geography, 2023-2031
  • FIGURE 14.5: Global Exosome Technologies Market by Products, 2023-2031
  • FIGURE 14.6: Global Market for Exosome-based Aesthetic Products by Segment
  • FIGURE 14.7: The Overall Exosome Market by Segment, 2031
  • FIGURE 15.1: Aethlon's Hemopurifier
  • FIGURE 15.2: qEV Zenco for Therapeutic Development
  • FIGURE 15.3: Robotic System for Diagnostic Development

INDEX OF TABLES

  • TABLE 2.1: Number of Molecular Contents identified in Exosomes
  • TABLE 2.2: Proteins Identified in Exosomes
  • TABLE 2.3: Common Lipid Contents of Exosomes
  • TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes
  • TABLE 2.5: Types of Therapeutic Cargos Loaded into Exosomes
  • TABLE 2.6: Differences between Cell Therapy and Exosome Therapy
  • TABLE 3.1: Hydrophobic Cargo Incorporated in Exosome Mmbrane
  • TABLE 3.2: Examples of Hydrophilic Cargo Loaded into Exosome Lumen
  • TABLE 5.1: Exosome Patent Applications by Jurisdiction as of June 23, 2024
  • TABLE 5.2: Exosome Patent Applicants
  • TABLE 5.3: Exosome Patent Inventors
  • TABLE 5.4: Exosome Patent Owners
  • TABLE 5.5: Legal Status of Exosome Patents as of June 22, 2024
  • TABLE 6.1: Exosome Clinical Trials by Phase of Study
  • TABLE 6.2: Exosome Clinical Trials by Funder Type
  • TABLE 6.3: Exosome Clinical Trials by Technology
  • TABLE 6.4: Current Status of Clinical Trials using Exosomes in Treating Diseases
  • TABLE 6.5: Clinical Trials using Exosomes for Diagnostic Studies
  • TABLE 6.6: Major Exosome R&D Companies
  • TABLE 6.7: Exosome Therapeutics in Preclinical Development
  • TABLE 8.1: Exosome Technology Platforms Developed by Commercial Companies
  • TABLE 10.1: Key Players in Therapeutic Exosome Research
  • TABLE 11.1: Most Common Targeted Exosome Biomarkers
  • TABLE 11.2: Exosomal Proteins for Diagnostic Applications
  • TABLE 11.3: Exosomal miRNAs as Cancer Diagnostic Agents
  • TABLE 11.4: A Sample of Exosome Diagnostic Clinical Trials
  • TABLE 11.5: Key Players in the Development of Exosome Diagnostics
  • TABLE 12.1: Key Players in Exosome-based Aesthetics
  • TABLE 13.1: Venture Capital Funding raised by Exosome Companies
  • TABLE 13.2: Partnership/Collaboration Deals in Exosome Space
  • TABLE 13.3: Acquisition Deals in Exosome Space
  • TABLE 13.4: Licensing Deals in Exosome Space
  • TABLE 13.5: Exosome Companies raising IPO Funds
  • TABLE 14.1: Likely-to-be Approved Exosome Therapeutics between 2026 and 2029
  • TABLE 14.2: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
  • TABLE 14.3: Global Market for Ready-to-Use Exosomes by Type, 2023-2031
  • TABLE 14.4: Global Exosome Therapy Market by Parent Cell Type, 2023-2031
  • TABLE 14.5: Global Market for Exosome Diagnostics by Geography, 2023-2031
  • TABLE 14.6: Global Exosome Technologies Market by Products, 2023-2031
  • TABLE 14.7: Global Market for Exosome-based Aesthetic Products by Segment
  • TABLE 14.8: The Overall Market for Exosomes
  • TABLE 15.1: Aegle's Product Pipeline
  • TABLE 15.2: Aruna Bio's Product Pipeline
  • TABLE 15.3: BreStem Therapeutics' Product Pipeline
  • TABLE 15.4: Capricor's Multi-Stage Pipeline
  • TABLE 15.5: Entelexo's Pipeline
  • TABLE 15.6: Evox Therapeutics' Product Pipeline
  • TABLE 15.7: EXO Biologic's Product Pipeline
  • TABLE 15.8: EXORPHIA's Product Pipeline
  • TABLE 15.9: ExoStemTech's Pipeline Products
  • TABLE 15.10: ILIAS' Product Pipeline
  • TABLE 15.11: INOVIQ's Development Pipeline
  • TABLE 15.12: NeurExo's Research & Development Programs
  • TABLE 15.13: NeuroDex's Pipeline
  • TABLE 15.14: ShiftBIO's Natural Drug Delivery Platform-based Programs
  • TABLE 15.15: Unicyte's Pipeline